Vistagen reports Q1 net loss of $15.1M; fasedienol Phase 3 data expected Q4 2025 and H1 2026

Vistagen Therapeutics, Inc.

2026-Q1 EPS reported -$0.47 revenue$244,000

Net loss $15.1M for fiscal Q1 ended June 30, 2025, vs $10.7M a year ago; R&D expense up to $11.7M.
Cash, cash equivalents, and marketable securities at $63.2M as of June 30, 2025.
Topline data from PALISADE-3 Phase 3 trial of fasedienol (SAD) expected Q4 2025; PALISADE-4 data H1 2026.
PH80 for menopausal hot flashes – IND preparation underway for further Phase 2 development.
Appointed Elissa Cote as Chief Corporate Development Officer in June 2025.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.